| Item | Cat. No. | Application | Isotype |
| Anti-ERBB2/CD340/HER2 mAbs [Coprelotamab Biosimilar] (MABL-4545) | MABL-4545 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-Misfolded TTR mAbs [Coramitug Biosimilar] (MABL-4546) | MABL-4546 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-Zaire Ebolavirus Glycoprotein mAbs [Cosfroviximab Biosimilar] (MABL-4547) | MABL-4547 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDL1/CD274 mAbs [Cosibelimab Biosimilar] (MABL-4548) | MABL-4548 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-IL7R/CD127 mAbs [Crebankitug Biosimilar] (MABL-4549) | MABL-4549 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-CD8A mAbs [Crefmirlimab Biosimilar] (MABL-4550) | MABL-4550 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-APP mAbs [Crenezumab Biosimilar] (MABL-4551) | MABL-4551 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-SARS-CoV-2 Spike RBD mAbs [Crexavibart Biosimilar] (MABL-4552) | MABL-4552 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-SELP/CD62 mAbs [Crizanlizumab Biosimilar] (MABL-4553) | MABL-4553 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-TNFRSF5/CD40 mAbs [Ciltistotug Biosimilar] (MABL-4524) | MABL-4524 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-SNCA/PARK1/PARK4 mAbs [Cinpanemab Biosimilar] (MABL-4525) | MABL-4525 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-ERBB2/CD340/HER2 mAbs [Cinrebafusp Biosimilar] (MABL-4526) | MABL-4526 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-TGFB1 (Canine) mAbs [Cirevetmab Biosimilar] (MABL-4527) | MABL-4527 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-EPCAM/CD326 mAbs [Citatuzumab Biosimilar] (MABL-4528) | MABL-4528 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IGF1R/CD221 mAbs [Cixutumumab Biosimilar] (MABL-4529) | MABL-4529 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E mAbs [Cizutamig Biosimilar] (MABL-4530) | MABL-4530 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa |
| Anti-C1S mAbs [Claseprubart Biosimilar] (MABL-4531) | MABL-4531 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-IL6 mAbs [Clazakizumab Biosimilar] (MABL-4532) | MABL-4532 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-SLC29A2 mAbs [Clervonafusp Biosimilar] (MABL-4533) | MABL-4533 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-DLL3;CD3&TNFRSF9/CD137/4-1BB mAbs [Clesitamig Biosimilar] (MABL-4534) | MABL-4534 | ELISA, FACS, Functional assay, in vivo binding | G4;G1, Kappa;Kappa |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
